239 related articles for article (PubMed ID: 11267168)
1. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation.
Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Neylan J; Roza A; Somberg K
Transplant Proc; 2001; 33(1-2):1011-2. PubMed ID: 11267168
[No Abstract] [Full Text] [Related]
2. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Roza A
Am J Transplant; 2003 Mar; 3(3):306-11. PubMed ID: 12614286
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
[TBL] [Abstract][Full Text] [Related]
7. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.
Folkmane I; Bicans J; Amerika D; Chapenko S; Murovska M; Rosentals R
Transplant Proc; 2001; 33(7-8):3209-10. PubMed ID: 11750377
[No Abstract] [Full Text] [Related]
8. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
9. Results of renal transplantation with different immunosuppressive regimens.
Folkmane I; Bicans J; Chapenko S; Murovska M; Rosentals R
Transplant Proc; 2002 Mar; 34(2):558-9. PubMed ID: 12009623
[No Abstract] [Full Text] [Related]
10. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
[TBL] [Abstract][Full Text] [Related]
11. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients.
Carmellini M; Vistoli F; Bellini R; Boggi U; Rindi P; Rizzo G; Mosca F
Transplant Proc; 1999; 31(1-2):1162-4. PubMed ID: 10083519
[No Abstract] [Full Text] [Related]
13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
14. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3.
Chowdhury S; Kode RK; Ranganna K; Damask AM; Lam A; Fyfe B; Stabler S; Kumar AM; Tomeny MB; Kumar MS; Pankewycz O
Transplant Proc; 2001; 33(1-2):1057-8. PubMed ID: 11267189
[No Abstract] [Full Text] [Related]
15. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation.
Boggi U; Vistoli F; Coppelli A; Marchetti P; Rizzo G; Mosca F
Transplant Proc; 2001; 33(7-8):3201-2. PubMed ID: 11750373
[No Abstract] [Full Text] [Related]
16. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
17. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
18. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
Mourad G; Rostaing L; Legendre C; Garrigue V; Thervet E; Durand D
Transplantation; 2004 Aug; 78(4):584-90. PubMed ID: 15446319
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients.
Shah MH; Bokhari MZ; Bokhari MT; Farooq A; Yousaf SM
Transplant Proc; 2003 Nov; 35(7):2737-8. PubMed ID: 14612099
[No Abstract] [Full Text] [Related]
20. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
Cransberg K; Bouts AH; Cornelissen EA; Lilien MR; Van Hoeck KJ; Hop WC; Nauta J
Transplantation; 2008 Nov; 86(9):1199-205. PubMed ID: 19005400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
